BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company focused on oncology and rare diseases, has announced it will release its Q3 2024 financial results on November 25, 2024, before U.S. markets open. The company will host a conference call at 8:30 a.m. EST, featuring CEO Philip Serlin. The call will be accessible via phone and webcast through the company's website, with replay available until November 27, 2024.
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), un'azienda biofarmaceutica in fase commerciale focalizzata sull'oncologia e sulle malattie rare, ha annunciato che pubblicherà i suoi risultati finanziari del Q3 2024 il 25 novembre 2024, prima dell'apertura dei mercati negli Stati Uniti. L'azienda ospiterà una teleconferenza alle 8:30 EST, con il CEO Philip Serlin. La chiamata sarà accessibile tramite telefono e webcast attraverso il sito web dell'azienda, con una registrazione disponibile fino al 27 novembre 2024.
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), una compañía biofarmacéutica en fase comercial enfocada en oncología y enfermedades raras, ha anunciado que publicará sus resultados financieros del Q3 2024 el 25 de noviembre de 2024, antes de la apertura de los mercados en EE. UU. La empresa llevará a cabo una conferencia telefónica a las 8:30 a.m. EST, con el CEO Philip Serlin. La llamada estará disponible a través de teléfono y webcast a través del sitio web de la compañía, con una repetición disponible hasta el 27 de noviembre de 2024.
BioLineRx (NASDAQ: BLRX) (TASE: BLRX)는 종양학 및 희귀 질환에 집중하는 상업 단계 바이오 제약 회사로, 2024년 3분기 재무 결과를 2024년 11월 25일 미국 시장이 열리기 전에 발표한다고 발표했습니다. 회사는 오전 8시 30분 EST에 CEO Philip Serlin이 진행하는 컨퍼런스 콜을 개최합니다. 이 콜은 회사 웹사이트를 통해 전화 및 웹캐스트로 접속할 수 있으며, 2024년 11월 27일까지 재생할 수 있습니다.
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), une société biopharmaceutique en phase commerciale axée sur l'oncologie et les maladies rares, a annoncé qu'elle publiera ses résultats financiers du T3 2024 le 25 novembre 2024, avant l'ouverture des marchés américains. L'entreprise animera une conférence téléphonique à 8h30 EST, avec le PDG Philip Serlin. L'appel sera accessible par téléphone et par webdiffusion via le site web de l’entreprise, avec un replay disponible jusqu'au 27 novembre 2024.
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), ein kommerzielles biopharmazeutisches Unternehmen, das sich auf Onkologie und seltene Krankheiten konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das Q3 2024 am 25. November 2024 vor der Eröffnung der US-Märkte veröffentlichen wird. Das Unternehmen veranstaltet um 8:30 Uhr EST eine Telefonkonferenz mit CEO Philip Serlin. Die Konferenz ist über Telefon und Webcast über die Unternehmenswebsite zugänglich, und die Wiederholung ist bis zum 27. November 2024 verfügbar.
- None.
- None.
Management to Hold Conference Call at 8:30 a.m. EST
The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.
CONTACTS:
John Lacey
BioLineRx
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2024-results-on-november-25-2024-302311395.html
SOURCE BioLineRx Ltd.
FAQ
When will BioLineRx (BLRX) release its Q3 2024 earnings?
What time is BioLineRx's (BLRX) Q3 2024 earnings call?
How can I access BioLineRx's (BLRX) Q3 2024 earnings call?
Until when will BioLineRx's (BLRX) Q3 2024 earnings call replay be available?
